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1. Introduction 
Gastric cancer remains a worldwide burden as a second leading cause of cancer death in 
both sexes (Globocan, 2011; Nobili et al., 2011). Although its incidence is in decline in 
developed countries, it is still the fourth most common malignancy in the world, behind 
cancers of the lung, breast, colon, and rectum (Globocan, 2011). The fall in its incidence is 
attributed mainly to the decline of the intestinal type of stomach cancer, whereas the 
incidence of the diffuse type has remained constant over time (Yamashita et al., 2011). On 
the other hand, there has been a progressive increase in the cardia and gastroesophageal 
junction adenocarcinoma (Milne et al., 2009; Yamashita et al., 2011). The exact cause of this 
shift in location is not known. The general decrease of gastric cancer frequency in developed 
countries is attributed to the changes in dietary habits and food preservation methods (Crew 
& Neugut, 2006; Kufe et al., 2003). The prevalence of gastric cancer varies throughout the 
world, with the highest rates reported in Korea, Japan, Central and South America, and 
Eastern Europe, whereas Western Europe, North America, Africa, Australia, and New 
Zealand are low incidence areas (Crew & Neugut, 2006; Tahara, 2008; Yamashita et al., 
2011). Despite the decrease in its incidence and improvements in diagnosis, curative 
surgery, and treatment, gastric cancer remains major health burden due to its poor 
prognosis (Smith et al., 2006; Yamashita et al., 2011).   
Adenocarcinoma is the major histological type of gastric cancer; accounting for 90% to 95% 
of all gastric malignancies, and this chapter will focus only on this type of gastric tumours 
(Hamilton & Meltzer, 2006). Adenocarcinoma develops from the glandular cells of stomach 
mucosa, while other rare stomach cancers develop in lymph tissue (lymphoma), hormone – 
producing cells (carcinoid tumours), muscle cells (soft tissue sarcomas) or certain nerve cells 
(gastrointestinal  stromal tumours or GIST) (Smith et al., 2006). Based on the widely used 
Lauren classification, adenocarcinomas are divided into two distinct pathological entities, 
intestinal and diffuse types, which have different clinicopathological and prognostic 
features (Yamashita et al., 2011). Intestinal type is associated with Helicobacter pylori 
infection, obesity and certain dietary factors, such as high intake of salt, smoked meats and 
food preserved with nitrites or nitrates, and is believed to arise through a long-term 
multistep progression from chronic gastritis to chronic atrophy to intestinal metaplasia to 
dysplasia (Crew & Neugut, 2006; Hamilton & Meltzer, 2006; Yamashita et al., 2011). 
Histologically it is well differentiated and occurs more commonly in older patients, males 
and blacks (Crew & Neugut, 2006). Diffuse type is poorly differentiated with infiltrating, 
www.intechopen.com
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
28
non-cohesive cells and is more frequent in younger patients (Crew & Neugut, 2006; Panani, 
2008). Studies showed that Helicobacter pylori infection also plays a role in the development 
of diffuse gastric cancer, through chronic inflammation, but without occurrence of 
intermediate steps, such as gastric atrophy and intestinal metaplasia (Milne et al., 2009).    
It is believed that the pathogenesis of gastric cancer represents a classic example of gene-
environment interactions (Panani, 2008). Epidemiologic studies have shown a reduction of 
its incidence in migrant populations, when they move from high-risk areas to low-incidence 
ones. Subsequent populations acquire risk levels similar to those in the host country, 
indicating the importance of environmental influences on its development (Crew & Neugut, 
2006; Matysiak-Budnik & Megraud, 2006). Therefore, it is generally acknowledged that both, 
environmental and genetic factors are implicated in the pathogenesis of gastric cancer 
development (Milne et al., 2009). Furthermore, several researchers believe that 
environmental factors have a greater influence on the development of intestinal type, 
whereas diffuse type might have a stronger genetic background (Matysiak-Budnik & 
Megraud, 2006; Milne et al., 2009). Nevertheless, despite tremendous efforts in the past few 
decades, there is still no clear agreement on the genetic and epigenetic changes underlying 
the initiation and progression of both types of gastric adenocarcinoma (Milne et al., 2009; 
Panani, 2008).  
This review is intended to focus on different molecular hypotheses of gastric carcinogenesis. 
New advances in the fields of high-throughput methodologies, functional genomics and 
molecular profiling will be discussed.   
2. Molecular mechanisms of gastric carcinogenesis 
Numerous cytogenetic and molecular genetic studies tested common cancer hypotheses, 
such as oncogene overexpression, suppressor, mutator, and methylator pathway 
hypotheses, but exact molecular mechanisms of gastric cancer development remain elusive. 
In nearly two decades of research a vast amount of articles referring to overexpression and 
silencing of genes was published (Resende et al., 2010). Several studies reported 
amplification and overexpression of growth factors, growth factor receptors, tyrosine 
kinases, nuclear factors, matrix metalloproteinases, cell cycle regulators cytokines and other 
genes (Panani, 2008; Tahara, 2008; Wu et al., 2010). Furthermore, other studies have shown 
that loss of heterozigosity (LOH) and inactivation of tumour suppressor genes seem to be 
involved in the development of gastric adenocarcinomas (Gazvoda et al., 2007; Juvan et al., 
2007; Panani, 2008; Resende et al., 2010). The presence of spontaneous DNA replication 
errors in simple repetitive microsatellite sequences indicated a novel pathway of 
carcinogenesis, microsatellite instability (MSI) (Loeb, 2001; Panani, 2008; Simpson et al., 
2001). It was found that it could be the consequence of defective DNA mismatch repair 
mechanism (MMR), caused by genetic alterations in MLH1, MSH2, PMS1, and PMS2 genes 
(Hudler et al., 2004; Loeb, 2001; Panani, 2008; Simpson et al., 2001). In recent years, 
epigenetic changes, such as promoter methylation, hypomethylation and histone acetylation 
have been also recognized in gastric carcinogenesis (Hudler et al., 2004; Mitani et al., 2005; 
Schneider et al., 2010; Suzuki et al., 2006; Yamamoto et al., 2011).  
In the 90‘s a model, describing genetic events of colorectal carcinogenesis, was suggested by 
Fearon and Vogelstein, which has shaped our understanding of the evolution of most types 
of malignancies today (Fearon & Vogelstein, 1990). The so-called 'Vogelgram' predicts that 
alterations in at least four to five cancer-related genes (oncogenes and tumour suppressor 
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genes) are needed for malignancy to occur, and that the total accumulation of changes rather 
than the order of their appearance is responsible for progression of the cancer (Fearon & 
Vogelstein, 1990).  
Although molecular mechanisms and alterations contributing to initiation and progression 
of gastric tumorigenesis are still not completely understood, it is now widely accepted that it 
is initiated by several genetic and epigenetic alterations that result in overexpression of 
oncogenes and growth factors, as well as impaired expression of tumour suppressor genes. 
It has also become evident that alterations in genome stability genes can initiate and 
accelerate these neoplastic processes (Nobili et al., 2011; Oda et al., 2005; Zheng et al., 2004). 
It is also important to note that the prevalence of these abnormalities varies between 
intestinal and diffuse types of gastric cancer (Hamilton & Meltzer, 2006). 
Recently, another type of genetic instability has been recognized as the most common 
feature of gastric cancers, namely chromosomal instability (CIN), leading to aneuploidy 
(Buffart et al., 2011; Nobili et al., 2011). New advances in high-throughput methodologies 
have shown that majority of solid tumours are characterized by gross chromosomal 
abnormalities, such as gain and/or loss of whole chromosomes or chromosomal segments 
(Duesberg & Rasnick, 2000; Gollin, 2005).  
2.1 Oncogenes  
Cell proliferation is tightly regulated through signal transduction pathways, which are 
regulated by growth factors and their receptors. Alterations in growth factors and other 
oncogenes result in constantly active genes or active under conditions in which the wild-
type genes are not. Oncogenes are mainly activated due to gene amplifications, intragenic 
mutations that regulate the activity of gene product or chromosomal translocations, all 
leading to overexpression of the oncoproteins. The occurrence and development of gastric 
cancer was found closely related to a variety of oncogenes, few of which are briefly 
discussed below.  
Ras family oncogenes play an important role in the pathogenesis of colon and pancreatic 
cancers and were reported, though less frequently, in gastric carcinomas (Pellegata et al., 
1992; Soh et al., 1993). The prevalence of alterations in HRAS (K-ras), which encodes a 
protein involved in cellular signal transduction pathways, appeared to be dependent of 
geographic and ethnic origins of gastric cancer cases. While HRAS mutations were rare in 
Western Europe and Japan, the prevalence in China was up to 30% (Deng et al., 1994; 
Hiyama et al., 2002; van Rees et al., 1999). Genetic changes in HRAS have been observed in 
gastric intestinal metaplasia and gastric adenomas, and could be an early event in the 
development of gastric cancer (Hirohashi & Sugimura, 1991; Osaki et al., 1996). Despite 
many studies focused on HRAS mutations, there is still some controversial data on the 
functional role of these mutations that needs to be elucidated. 
Overexpression or activation, due to either amplification or mutation of genes of some 
tyrosine kinases (hepatocyte growth factor receptor (MET or c-met), fibroblast growth factor 
receptor 2 (FGFR2 or K-sam), human epithelial growth factor receptor 2 (HER2), and 
epithelial growth factor receptor (EGFR)) could be associated with human gastric cancer. 
Both, HER2 and EGFR, were found overexpressed in gastric cancer, with prevalence in the 
intestinal type cancers (Garcia et al., 2003). Receptors have an intracellular domain with 
tyrosine kinase activity and EGFR can bind ligands with its extracellular domain, which 
induces homodimerization of the receptor and generates autophosphorylation, initiating 
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several signalling cascades that lead to DNA synthesis and cell proliferation. 
Overexpression of EGFR promotes cell migration, angiogenesis and inhibits apoptosis and 
has been observed in up to 47% of gastric cancers. Moreover, it was found to correlate with 
disease progression and poor clinical outcome (Malden et al., 1989; Yonemura et al., 1992; 
Yoshida et al., 1990). HER2 does not bind to any known ligand, but it is known to 
heterodimerize with other members of the family, especially when it is overexpressed. The 
protein has been reported to be overexpressed or activated in 19% of gastric cancer cases. 
Studies suggest that overexpression of HER2 might be prognostic factor for intestinal-type 
gastric cancer associated with shorter relapse-free survival and overall survival (Vizoso et 
al., 2004; Zhang et al., 2009).  
Abnormalities in genes, such as FGFR2 (K-sam), belonging to fibroblast growth factor 
receptor family, are associated with diffuse-type gastric cancer. Activation of FGFR2 has 
been found in approximately 50% of diffuse type gastric cancers, and was associated with 
neoplastic progression and metastasis (Hara et al., 1998; Hattori et al., 1996; Werner et al., 
2001). 
The oncogene MET (c-met) encodes a receptor with tyrosine-kinase activity that binds 
hepatocyte growth factor. Aberrantly active receptor was preferentially found in intestinal-
type gastric cancer tumours and was correlated with poor prognosis (Nakajima et al., 1999; 
Tsugawa et al., 1998). Employing a simple method of fluorescent multiplex RT-PCR assay 
and capillary electrophoresis separation we found overexpression of MET in 56% of 
Slovenian patients with gastric cancer (Rajcevic et al., 2007; Rajcevic et al., 2001). MET 
amplification could constitute an important biomarker for selecting patients for a targeted 
therapy, because it has been observed that a fraction of gastric cancer cell lines appeared to 
be exquisitely sensitive to a specific MET inhibitor (Smolen et al., 2006). 
Vascular endothelial growth factor (VEGF), a pro-angiogenic molecule, was found 
frequently overexpressed in poorly differentiated gastric cancer (Brown et al., 1993; 
Scartozzi et al., 2004; Tian et al., 2001; Yamamoto et al., 1998). Recently, a VEGF +1612G/A 
gene polymorphism was found to be associated with gastric cancer in Chinese Han patients 
and was previously shown to affect VEGF plasma levels (Zhou et al., 2011). Several other 
oncogenes have been found overexpressed in gastric carcinomas (Nobili et al., 2011; Rajcevic 
et al., 2007; Tahara, 2004). Nevertheless, years of research have shown that overexpression of 
oncogenes is not the sole mechanism implicated in gastric cancer pathogenesis.  
2.2 Suppressor phenotype 
Tumour suppressor genes are targeted in the opposite way than oncogenes. Molecular 
abnormalities that result in a truncation of the proteins, deletions or insertions or epigenetic 
silencing, reduce the activity of the gene product. Generally, alterations in both alleles are 
required to confer impairment of the gene product, except in the case of haplo-insufficient 
genes (Dang et al., 2008; Vogelstein & Kinzler, 2004). Inactivation of the wild-type allele 
arises due to allelic loss, termed also loss of heterozygosity (LOH) or mutations (Knudson, 
1993). The suppressor phenotype in gastric cancer is characterized by inactivation of 
suppressor genes, such as TP53 (p53), APC, MCC, DCC, CDH1, Rb1, FHIT, and other 
(Hamilton & Meltzer, 2006; Nobili et al., 2011). 
In our study we evaluated LOH on loci associated with the following tumour suppressors: 
TPp53, APC, nm23, and RB) and found that 52% of all cases exhibited LOH in at least one 
locus (Gazvoda et al., 2007). The highest frequency of LOH was at APC locus (36%), 
www.intechopen.com
 
Genetic Instability in Gastric Cancer 
 
31 
followed by TP53-1 (33%), nm23 (33%), TP53-2 (24%) and RB (24%). Interestingly, 5% of the 
samples exhibited MSI on all the evaluated loci (in LOH as well as in MSI evaluation). These 
samples were associated with clinicopathological features that differed from the rest. All 
tumours belonged to intestinal type, displayed expansive growth and were mostly tubular. 
Furthermore, we found that LOH on loci TP53-1 and TP53-2 was associated with more 
expansive growth and LOH on TP53-1 locus tended to be associated with intestinal type 
tumours. In contrast, tumours without LOH on TP53-1 locus were associated with 
ulcerating, infiltrating type of gastric adenocarcinoma (Gazvoda et al., 2007). 
The TP53 gene encodes a main regulator of cell growth and division, and its function in 
intestinal type of gastric cancer is mainly altered due to LOH and mutations. When protein 
p53 is impaired, the cells may not be able to induce apoptosis and control tumour growth 
(Vousden & Prives, 2005). Studies showed that mutations in TP53 are present in a range of 
40%-70% of early and advanced gastric cancers, and inactivation of TP53 resulting from 
LOH is found in 60%-70% of intestinal-type gastric cancers, thus making this gene among 
the most frequently mutated genes in cancers (Hamilton & Meltzer, 2006; Werner et al., 
2001). It was suggested that accumulation of mutations in TP53 is involved in initiating 
carcinogenic processes, though not all studies are in agreement with this hypothesis (Liu et 
al., 2001; Zwick et al., 1997). The expression of p53 protein can be easily detected by 
immunohistochemical staining, because mutations in TP53 gene increase the half-life of its 
product, and it was postulated that it could be used as a biomarker in a clinical setting 
(Zheng et al., 2004). However, there are conflicting results regarding the prevalence and of 
TP53 mutations and its expression and their relationship to clinicopathological features of 
gastric cancer (Panani, 2008). We and some other researchers found that the TP53 mutational 
status was not in association with p53 expression (Bataille et al., 2003; Juvan et al., 2007; 
Panani, 2008). Furthermore, we found that positive TP53 expression was associated with 
poorer survival, which was accordance with some other studies (Bani-Hani et al., 2005; 
Lazar et al., 2010). On the other hand, other studies did not reveal this association, therefore, 
the prognostic value of TP53 remains controversial (Panani, 2008).    
Loss of APC gene function was first identified in 60%-80% of patients with familial 
adenomatous polyposis-associated colorectal cancers (Kinzler et al., 1991; Lynch & Lynch, 
1998). Mutations and LOH of the gene were also reported in more than 50% of gastric 
cancers of intestinal type (Tahara, 1995; Wright & Williams, 1993). Functional product of 
APC gene targets ┚-catenin for ubiquitination, and thus prevents ┚-catenin associated 
induction of genes involved in growth control (Caca et al., 1999; Park et al., 1999). 
E-cadherin, encoded by CDH1 gene, is an adhesion molecule expressed from epithelial cells, 
which plays a crucial role in epithelial structural integrity and was found to be implicated in 
carcinogenesis. Germline mutations in CDH1 were first described in patients with 
hereditary diffuse type gastric cancer, however the rate of CDH1 mutations in sporadic 
gastric cancer was found to be as high as 50%, and reduced expression of E-cadherin protein 
was found in 51% of diffuse type gastric cancers (Becker et al., 1994; Guilford et al., 1998; 
Xiangming et al., 1999). Susceptible individuals with a germline mutation in tumour 
suppressor gene CDH1 require the inactivation of the second allele due to somatic mutation 
or DNA methylation, rendering E-cadherin completely inactive (Becker et al., 2000). 
Abnormal expression of E-cadherin is thought to promote metastatic ability of gastric cancer 
cells (Kanai & Hirohashi, 1997).  
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2.3 Alterations in other genes 
Genetic and epigenetic abnormalities have been found in numerous other genes that 
participate in proliferation, invasion and metastasis, such as cell cycle regulators, cell-
adhesion molecules, growth factors, cytokines, nuclear factors, matrix metalloproteinases, 
DNA repair genes, and apoptosis regulators (Nobili et al., 2011; Tahara, 2004; Yokozaki et 
al., 2001). For example, cyclin E1 together with cyclin-dependent kinase, CDK2, promotes 
the entry into the S-phase of the cell cycle, and it was found overexpressed in one third of 
gastric cancer cases. Amplification of this gene was found to correlate with tumour 
aggressiveness (Jiaqing et al., 1998; Nobili et al., 2011; Xiangming et al., 2000). In our study 
we observed overexpression of cyclin E1 in 42% of patients with gastric cancer and in 57% of 
patients with precancerous lesions, indicating that abnormalities in this gene could be early 
event in gastric carcinogenesis (Rajcevic et al., 2007). Moreover, we also found 
overexpression of epidermal growth factor family members, such as TDGF1 and EGF, and 
NRG1, signalling protein, that mediates cell-cell interactions and plays critical roles in the 
growth and development of multiple organ systems (Rajcevic et al., 2007). Several other 
genes have been reviewed extensively elsewhere (Nobili et al., 2011; Resende et al., 2010; 
Tahara, 2004; Wu et al., 2010; Yokozaki et al., 2001).  
2.4 MSI and mutator phenotype 
Molecular abnormalities in oncogenes and tumour suppressor genes drive the neoplastic 
process by increasing tumour growth. The increase is achieved by activating of genes that 
drive the cell cycle or by inhibiting normal apoptotic pathways (Vogelstein & Kinzler, 2004). 
The third class of genes that contribute to cancer development are the stability genes, which, 
when mutated, promote tumorigenesis in a completely different way. They keep genetic 
alterations to a minimum, and thus, when they are inactivated, mutations in oncogenes and 
tumour suppressor genes occur at a higher rate (Freiberg, 2003). As with tumour suppressor 
genes, both alleles must be inactivated for physiologic effect to result.  
Mismatch repair (MMR) genes are an example of genome stability genes and molecular 
inactivation of these genes is a hallmark of so-called mutator pathway, which results in 
microsatellite instability (MSI) or mutator phenotype. Microsatellites are short tandem 
repeats abundant throughout the genome. They are polymorphic among individuals, but 
their length is stable in every noncancerous tissue within a given individual. Patients with 
MSI phenotype exhibit a high frequency of changes in length of microsatellites within a 
tumour tissue compared to normal tissue, due to slippage of DNA polymerase during DNA 
replication on repetitive sequences, which leads to insertion or deletion of nucleotides. In 
short, MSI phenotype is characterized by appearance of new alleles not present in the 
normal genotype. These postreplicational DNA errors are detected and repaired by a 
complex of MMR proteins, rather than proofreading activity of the polymerase. Inactivation 
or deficiency of one or more MMR genes, particularly MLH1 or MSH2, leads to 
manifestation of MSI phenotype in gastric cancer. As shown in Figure 1, MSI often leads to 
additional genetic changes and allelic losses, due to frameshift mutations in coding 
repetitive sequences of genes involved in cell growth regulation, apoptosis and DNA repair 
(Buermeyer et al., 1999; Ottini et al., 2004). Remarkably, every human MMR gene except 
MLH1 includes a mononucleotide repeats, suggesting that the MMR process becomes 
increasingly defective with subsequent losses of involved proteins (Perucho, 1996). 
www.intechopen.com
 
Genetic Instability in Gastric Cancer 
 
33 
Impairment of MMR, eventually leading to cancer development, can occur: 1) by mutational 
inactivation of one or two MMR genes, or 2) by epigenetic inactivation of MMR genes. In 
gastric cancer, functional inactivation of MMR is mainly caused by latter. Epigenetic 
hypermethylation of MLH1promoter has been found to be responsible for the development 
of the majority, more than 50%, of MSI-H positive gastric cancers, whereas mutations in 
MLH1 and MSH2 are being reported in 12-15% of gastric cancer exhibiting MSI-H 
phenotype (Bacani et al., 2005; Wu et al., 2000; Yamamoto et al., 1999) (Figure 1). Silencing of 
multiple genes, including known tumour-related genes such as CDKN2A (p16), hMLH1, 
THBS1, and CDH1, due to promoter hypermethylation, is an important epigenetic event in 
stomach carcinogenesis and was shown to occur in early stages of gastric cancer 
development. This pathway of methylation of CpG islands characterizes alternative 
molecular phenotype of gastric cancer, referred to as the CpG island methylator phenotype 
(CIMP) (Nobili et al., 2011; Oue et al., 2001; Resende et al., 2010). 
2.4.1 MSI analysis 
MSI can be detected with polymerase chain reaction (PCR), where each microsatellite under 
investigation is amplified using specific primers. Lengths of PCR obtained products are 
usually assessed and compared between normal and tumour tissues from each individual 
using a simple and cost effective fluorescent multiplex PCR, followed by capillary 
electrophoresis separation (Gazvoda et al., 2007; Suraweera et al., 2002). Because of a  huge 
number and diversity of microsatellite regions in the human genome, it is difficult to 
determine the prevalence of MSI in human cancers and its incidence varies depending on 
which loci are investigated (Lawes et al., 2003). To overcome this confusion, a standard 
panel of microsatellite markers, including mononucleotide repeats (BAT25 and BAT26) and 
dinucleotide repeats (D2S123, D5S346 and D17S250) has been recommended to identify MSI 
phenotype (Nobili et al., 2011). Cancers were subdivided in three groups based on the 
number of markers displaying instability: those demonstrating instability in > 30-40% of the 
loci investigated were classified as high-level MSI (MSI-H); those demonstrating instability 
in <30-40% of the loci investigated were classified as low level MSI (MSI-L); and stable 
cancers (MSS) showing no instability (Boland et al., 1998). Although these criteria were 
initially aimed at identifying MSI positive colorectal cancer, they were also successfully used 
for detecting MSI-H gastric cancers. Incidence of MSI-H has been observed in range 2-18% 
of gastric cancer cases, depending on the ethnic background.  In Japan the incidence of MSI-
H phenotype in patients with gastric cancer was reported in 5% of cases, whereas in 
Western populations it was ranging from 2 to 15% (Gu et al., 2009; Hudler et al., 2004; Leung 
et al., 1999; Pedrazzani et al., 2009; Schneider et al., 2000; Zhou et al., 1998). Moreover, 
studies reported 3-fold higher prevalence of MSI-H status in intestinal rather than diffuse-
type gastric cancers (Leite et al., 2011). As reviewed by Lawes et al., patients with gastric 
cancer that exhibit MSI-H phenotype were associated with a better survival (64-88%) when 
compared to MSS counterparts (39-53%) (Lawes et al., 2003). Furthermore, we and other 
researchers have found that MSI-H phenotype was not associated with LOH-H phenotype, 
which is in agreement with other studies proposing that the mutator and suppressor 
pathways are independent of each other at least in the early stages of gastric carcinogenesis 
(Gazvoda et al., 2007; Kim et al., 2001). Likewise, patients with LOH-H were associated with 
MSI-L or did not show MSI (microsatellite stable, MSS) on evaluated loci. In our study we 
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evaluated MSI on loci BAT25, BAT26, BAT40, D2S123, D3S1277, and D10S107, and as 
mentioned before, LOH on loci, associated with tumour suppressors. Interestingly, the 
highest frequency of MSI was found at RB locus (21%), which was initially tested for LOH, 
followed by BAT25 (15%), D3S1277 (14%), D2S123 (13%), D10S107 (13%), BAT40 (12%) and 
BAT26 (10%) (Gazvoda et al., 2007). We observed that in our study BAT26 was the most 
informative locus. We also correlated MSI with clinicopathological features and found that 
MSI-L phenotype was associated with diffuse or mixed types of gastric cancers.  
 
 
 
Fig. 1. Mutator pathway overlapping with suppressor and methylator pathways in gastric 
tumorigenesis. These changes should not be considered a specific sequence of alterations, 
but rather an overall collection of abnormalities that contribute to the pathogenesis of gastric 
cancer (Adopted from Boland & Goel, 2010). 
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It has recently become evident that dinucleotide repeats are less sensitive than 
mononucleotide repeats for detection of MSI-H, therefore revised criteria proposes the use 
of a mononucleotide markers in order to define MSI-H instability (Umar et al., 2004). A 
panel of five mononucleotide repeats (BAT25, BAT26, NR-21, NR-22 and NR-24) that may 
be more  instrumental for detecting MSI-H status in humans has been suggested (Buhard et 
al., 2004). It has been further demonstrated that these markers are quasimonomorphic in 
1206 studied individuals from 55 different populations worldwide, and can therefore be 
used for MSI-H determination without the requirement for matching normal DNA (Buhard 
et al., 2006). By adopting the panel, MSI-H phenotype was reported in a range from 5% to 
50% of all gastric carcinomas with significant differences in various population groups 
(Leite et al., 2011; Ottini et al., 2004; Simpson et al., 2001). 
2.4.2 Mutational impairment of MMR activity and pathogenic significance of observed 
alterations 
The most common inherited condition that gives rise to MSI positive cancers is Lynch 
syndrome, an autosomal dominant disease, also referred to as Hereditary Non-polyposis 
Colorectal Cancer (HNPCC), where gastric cancer is a common neoplasia, occurring in 6% of 
Lynch syndrome cases (Percesepe et al., 2001; Samowitz et al., 2001). Predisposed 
individuals carry a recessive, first-hit germline mutation in the MMR genes, including large 
genomic rearrangement, which account for 5-20% of all mutations. In reference of 
Knudson's hypothesis, the MSI-H phenotype requires the "second hit" inactivation of the 
responsible MMR gene for development of malignant phenotype.  
In Lynch syndromes, somatic inactivation of the remaining wild-type allele can occur due to 
different mechanisms: loss of heterozygosity (LOH), somatic mutation and promoter 
methylation (Imai & Yamamoto, 2008). The relative risk of gastric cancer development in 
Lynch syndrome individuals has been reported to be 4-19-fold higher, compared to general 
population, suggesting that screening for MMR mutations in predisposed carriers could be 
of importance for the detection of predisposed individuals (Gylling et al., 2007). Particularly, 
patients with MSI-positive gastric carcinomas, but lacking MLH1 promoter 
hypermethylation are regarded as potential germline MMR-related mutation carriers.  
Majority of MMR alterations, found in patients with Lynch syndrome are known to be 
pathogenic as they result in premature termination of protein synthesis and thus loss of 
MMR activity. However, hundreds of MMR variants that do not lead to truncation of the 
respective MMR protein have been identified in Lynch cancer cases and their pathogenic 
significance is often difficult to establish on clinical samples alone. 
Information on functional nature of MMR alterations is essential for accurate early diagnosis 
and prognosis as well as for proper genetic counselling for members from affected families. 
Therefore in the past decade, many functional assays have been developed to ease the 
interpretation of pathogenicity of unclassified variants (UVs). Recent and some of the most 
recognized in vivo and in vitro assays together with available in silico algorithms are 
summarised in Table 1.  
While many in vitro assays characterize specific biological functions of MMR proteins, in 
vivo tests strive to assess the MMR repair capacity as a complex cellular process (Ou et al., 
2007). Since efficiency of MMR repair relies on several successfully completed biochemical 
events of involved proteins (e.g. protein expression levels and stability, localization of MMR 
protein to the nucleus, heterodimerization ability and effective recognition and repair of the 
DNA lesions, etc.), in vivo approaches are preferable and are either cell line- or yeast-based. 
However, all assays have their limitations and problems, mostly concerning toxic episomal 
overexpression of MMR proteins and lack of evolutionary conserved regions between yeast 
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and human MMR proteins at the regions of interest. Moreover, since variety of strategies 
have been used, it is difficult to establish and compare clinical significance of analysed 
variants. Finally, it is also not easy to determine sensitivity and specificity of these tests, 
therefore results should still be utilized with caution and interpreted alongside clinical data 
of the affected carriers. 
 
Assay 
type  
Biochemical 
feature analysed
 
Assay 
 
References 
In vitro Protein-protein 
interaction 
GST pull-down  Raevaara, 2005; Guerette, 
1999; 
Belvederesi, 2006; Perera, 
2008 
Expression of MMR genes in 
human cell lines 
Trojan, 2002 
Protein 
expression 
Western blotting Takahashi, 2007 
mRNA splicing pCAS minigene Tournier, 2008 
MMR activity Cell-free assay w/ protein 
extracts 
Takahashi, 2007; Raevaara, 
2005;  
In vivo Protein-protein 
interaction 
Human-yeast hybrid MLH1 in 
yeast 
Kondo, 2003; 
Protein 
expression 
Immunohistochemical staining Leite, 2011 
Intracellular 
localization 
Fluorescence microscopy Raevaara, 2005 
mRNA splicing
 
In vivo splicing assay in human 
cells 
Auclair, 2006; Sharp, 2004; 
Arnold, 2009 
MMR activity 
 
 
Yeast-based chromosome-
integrated hMMR gene 
Vogelsang, 2009;  
Vogelsang, 2010 
Dominant mutator effect Raevara, 2005;Takahashi, 
2007; Shimodaira, 1998 
Functional assay using yeast Ellison, 2001;Wanat, 2007 
Utility of MLH1-deficient cells Blasi, 2006 
In silico Effect of amino 
acid substitution 
on protein 
functions 
 
SIFT  Kumar, 2009; Ng, 2003 
PolyPhen Ramensky, 2002 
MAPP-MMR Chao, 2008 
Align GVDV Tavgtigian, 2006; Mathe, 
2006 
mRNA splicing NNSPLICE Sharp, 2004 
Table 1. Compilation of functional assays used in characterizing pathogenic significance of 
MMR variants found in Lynch syndrome patients. 
We have recently described an in vivo yeast-based functional approach, expressing human 
MMR genes in yeast, enabling all variants found within the coding region of the MMR gene 
to be analysed. With chromosomal integration of relevant human MMR genes we obtained 
their stable expression throughout the experiment (Vogelsang et al., 2009). With our 
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approach we have functionally characterized four missense MLH1 variants, which we 
previously identified in MSI-H positive gastric cancers with limited MLH1 
hypermethylation. We also assessed two of the variants, which were described for the first 
time in our study (Hudler et al., 2004). We have shown that identified  missense mutations 
were not causally associated with MSI-H phenotype in analysed gastric cancer tissues 
(Vogelsang & Komel, 2010).  
2.5 Chromosomal instability (CIN) and aneuploidy 
In contrast to MSI, CIN is characterized by gross chromosomal abnormalities, such as gain 
or loss of whole chromosomes and/or fractions of chromosomes (LOH, amplifications, 
translocations) (Martin et al., 2010). Aneuploidy is the state of altered chromosome number 
in malignant cells (Pino & Chung, 2010). Studies showed that MSI phenotype is 
characteristic for hereditary type of gastric cancer, developed in the context of Lynch 
syndrome, and a smaller subset of sporadic cancers ranging from 15% to 35% (Panani, 2008). 
CIN, however, has been recently recognized as the most common feature of sporadic gastric 
cancers, and has been reported in up to 84% of gastrointestinal tumours (Grabsch et al., 
2004; Ottini et al., 2006). 
Several techniques, such as karyotyping, cytometry, detection of LOH, and fluorescent in 
situ hybridization (FISH) have been developed to measure CIN and some of them have 
already been successfully transferred to clinical practice. New methods, such as CGH arrays 
and copy number variation analysis (CNV), have advanced the field, due to their ability to 
detect chromosomal abnormalities with higher resolution and accuracy (Pino & Chung, 
2010).     
CIN has been recognized as valuable prognostic factor and tumour stage indicator in gastric 
cancers, although in the study of Birkbak et al. it has been found that intermediate CIN had 
more impact on poor prognosis than extreme CIN phenotype  (Birkbak et al., 2011; Suzuki et 
al., 2003). Furthermore, it has been found that DNA copy number changes are not uniform 
in gastric cancers and subgroups with different patterns of DNA copy number alterations 
have been recognized, which have been associated with prognosis, lymph node status and 
metastasis (Buffart et al., 2007b; Kang et al., 2006; Morohara et al., 2005; Panani, 2008; Weiss 
et al., 2004; Wu et al., 2002).  
Buffart et al. explored the differences in DNA copy number by CGH arrays and reported 
that the mean number of chromosomal events was lower in adenomas compared to gastric 
carcinomas, suggesting that distinct losses and gains on chromosomes likely represent early 
events in carcinogenesis (Buffart et al., 2007b). In another study they compared CGH 
profiles of gastric cancers in young and old patients (Buffart et al., 2007a). They found out 
that chromosome regions 11q23.3 and 19p13.3 contributed most to age-related differences in 
tumour profiles and that tumours of younger patients showed gains in chromosomal 
regions 6p21, 9p34, 11p15, 11q23, 17p13, 19p13, and 22q13, whereas in the majority of older 
patients normal copy status was observed. They concluded that these differences in genomic 
profiles likely reflect different pathogenic mechanisms of the disease.  
Varis et al., similarly observed that the most frequent cytogenetic aberrations were gains 
seen at 17q, 19q, and 20q in younger patients (Varis et al., 2003). They also found  
that DNA copy number changes were mostly detected in intestinal or mixed types of 
tumours.  
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Tsukamoto et al. observed higher frequencies of DNA copy number aberrations, especially 
in the case of 20q13 chromosome gain, which was detected in 97% of cases, compared to 
other studies (Tsukamoto et al., 2008). They used laser microdissection method to isolate 
tumour cells, therefore their samples contained fewer cells from tumour microenvironment. 
They also identified 114 upregulated candidate genes located in regions of amplification and 
11 down-regulated genes located in regions of deletion.  
Several other studies reported different DNA copy number changes in patients with gastric 
cancer (Buffart et al., 2007b; Hou et al., 2008; Junnila et al., 2010; Kimura et al., 2004). Hou et 
al., for example, used an integrated approach using CGH and 100K SNP arrays, FISH, 
reverse transcription PCR, Western immunoblotting, and siRNA-mediated gene knockdown 
to determine and identify potential overexpressed genes in region 6p11p12, which they 
found to be amplified in their study (Hou et al., 2008). They identified RAB23, which could 
be implicated in invasion.  
Despite the remarkable effort made by researchers to identify significant chromosomal 
aberrations in gastric cancers and to correlate them with clinicopathological features, the 
results are still inconclusive and not consistent with each other (reviewed in Nobili et al., 
2011; Panani, 2008).  
2.5.1 LOH 
As stated before, LOH studies have already revealed several chromosomal loci with 
significant allelic losses, facilitating the identification of tumour suppressor genes, which 
could be important in gastric tumorigenesis (Gazvoda et al., 2007; Juvan et al., 2007; Kim et 
al., 1991; Kondo et al., 2005; Panani, 2008; Tamura, 2006). LOH is also a marker of 
chromosomal instability and might indicate a second inactivational hit of a cancer 
suppressor gene. Allelic losses are typically detected by using highly polymorphic 
microsatellite sequences that are dispersed throughout the human genome. Several LOH 
studies demonstrated that the extent of chromosomal loss appeared to be of prognostic 
significance (French et al., 2004; Gazvoda et al., 2007; Koo et al., 2004). It was established that 
there was a trend of two distinct subtypes, high-level LOH (named LOH-H) and low-level 
LOH (named LOH-L), being correlated with intestinal or mixed and diffuse growth 
patterns, respectively (Hong et al., 2010). In our study we also found out that LOH-H was 
associated with intestinal type of gastric cancer (Gazvoda et al., 2007). LOH has been shown 
to relate to cancer progression, where a transition from LOH-L to LOH-H is thought to 
reflect an increase in chromosomal instability during tumour advancement. These findings 
on LOH events suggest that the degrees of allelic loss may have an influence on the clinical 
course of gastric cancer.   
2.5.2 Aneuploidy 
Although some opinions still diverge regarding the clinical impact of aneuploidy alone 
(mostly measured by FISH, flow cytometry or image cytometry), recently there are reports 
pointing out that it could be of importance as a predictive marker in gastric cancer, and its 
potential clinical practicability in pre-malignant disease to stratify patients by their cancer 
risk. It is important to note recent evidence supporting the hypothesis of stepwise ploidy 
progression: from diploid or minor aneuploid in most early cancers to aneuploid in most 
advanced cancers (Duesberg et al., 2005). As a progressive increase in the severity of 
aneuploidy with neoplastic progression has been observed, it has thus been shown to be a 
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useful prognostic indicator for patient classification as low or high-risk cases for cancer 
development (Russo et al., 2000; Yasa et al., 2005).  
Interestingly, aneuploidy was found in human tumours more than 100 years ago by von 
Hansenmann and Boveri (Duesberg & Rasnick, 2000; Ricke et al., 2008). However, in the last 
decades, the research was oriented towards oncogenes and tumour suppressors’ hunt, and 
in identifying mutator and methylator pathways of gastric carcinogenesis. Yet to date, not 
one subtype of gastric adenocarcinomas has been completely described and no cancer-
causing genes or combination of genes have been found to be specific for gastric cancers, 
although a number of mutations and other genetic changes have been described (Duesberg 
& Rasnick, 2000; Nobili et al., 2011; Panani, 2008; Weber, 2002).  
Recently, it has been found that aneuploidy, either in the form of LOH or gross 
chromosomal copy number changes, stands out as the most consistent marker of neoplastic 
cells in solid tumours (Duesberg & Li, 2003; Ottini et al., 2006). Indeed, several studies 
confirmed a high frequency of aneuploidy in sporadic gastric cancers, even up to 84% 
(Belien et al., 2009; Buffart et al., 2007b; Buffart et al., 2011; Grabsch et al., 2004; Russo et al., 
2000).   
2.5.3 Mechanisms leading to chromosomal instability 
The mechanisms leading to abnormal chromosome content and other chromosomal 
abnormalities are poorly understood, although it is now believed that CIN might, through 
stepwise clonal progression, lead to oncogene activation, tumour suppressor inactivation 
and alterations in other crucial genes, implicated in establishing the malignant phenotype of 
cells. Several different mechanisms have been proposed by researchers, such as telomere 
dysfunction, defective DNA damage response, impaired chromosomal segregation, and 
aberrations in cell cycle regulators (Castro et al., 2007; Gollin, 2005; Grabsch et al., 2004; 
Yasui et al., 1999).  
Lately, the attention of researchers in the field of epithelial tumours, including gastric 
adenocarcinomas, has focused on genetic changes in mitotic genes, with emphasis on 
chromosome segregation. Segregation is one of the fundamental processes in cells, which 
are rapidly dividing, such as gastric epithelial cells. Therefore, if regulation mechanisms, 
governing this process are damaged, the cells might proceed through cytokinesis with DNA 
or spindle errors and thus could inherit unrepaired mutations or gain an abnormal number 
of chromosomes (aneuploidy) (Schmit & Ahmad, 2007). However, the molecular defects 
underlying CIN and aneuploidy and weather it is a cause or consequence of tumour 
phenotype are not completely clear. At least two possible mechanisms for CIN development 
have been suggested: mutations and/or polymorphisms in mitotic genes, implicated in 
chromosome segregation, or the activity of carcinogens on susceptible genetic background 
of individuals. (Duesberg et al., 2005; Iovino et al., 2006).  
Studies on several animal species and humans showed that certain genetic mutations and 
polymorphisms in genes involved in segregation of chromosomes might cause an increased 
incidence of a particular tumour type (Shepard et al., 2007; Tomonaga & Nomura, 2007). 
Kim et al. analysed expression of MAD2L1, a component of the mitotic spindle assembly 
checkpoint, and kinase gene BUB1, involved in activating the spindle checkpoint. They 
found mutations in MAD2L, whereas they did not detect any mutations in BUB1.  
Grabsch et al., on other hand, observed overexpression of BUB1 protein in gastric cancers, 
which was significantly higher in tissues of patients with diffuse type adenocarcinomas 
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(Grabsch et al., 2004). However, their study did not reveal any association between BUB1 
protein expression level and DNA ploidy status of examined tumour types.  
Aurora kinase A (AURKA or STK15) located at 20q13, a region that is frequently amplified 
in gastric cancer, has been found overexpressed in stomach adenocarcinomas (Dar et al., 
2008). Functional analysis of upregulated AURKA gene, done by the same researchers, 
revealed a possible novel oncogenic pathway, involved in gastric carcinogenesis. AURKA 
overexpression led to a significant increase in mRNA levels of several direct targets of the ┚-
catenin/TCF transcription complex (cyclin D1, MYC, MYC-binding protein, CLDN1, FGF18, 
and VEGF).  
However, these and several other studies, explored overexpression and/or mutations of 
these genes, which could already be the consequence of CIN. Therefore, it has been 
proposed that minor alterations in mitotic genes could contribute to the onset of cancer 
(Frank, 2004). The mounting evidence is suggesting that subtle variations, such as single-
nucleotide polymorphisms (SNPs) or non-lethal mutations, might induce CIN and 
aneuploidy. This hypothesis of low-penetrance allelic variants or risk alleles is further 
supported by the fact that non-heritable cancers usually develop in elderly, whereas 
dominant mutations in oncogenes and tumour suppressors usually induce the disease early 
in life (Duesberg & Rasnick, 2000; Frank, 2004). Minor genetic variants in mitotic genes 
could in combination with environmental factors modulate mitotic pathways, and could 
thus exert minor changes in the DNA of replicating epithelial cells. The search for these 
changes has begun only recently, and further investigations are needed to clarify these 
aberrations and their involvement in carcinogenesis.  
In our study, we genotyped two polymorphic sites, T91A (F31I) and G169A (V57I) in serine-
threonine-kinase STK15 (AURKA), which is involved in the regulation of several cell cycle 
events (Hudler et al., 2009). It is responsible for the functioning of centrosome, for 
microtubule formation and stabilization at the spindle pole throughout all phases of 
segregation, and for chromosome segregation during anaphase. We found a putative 
protective role of the genotype A/T (F31I) in examined population of gastric cancer patients. 
We also found a weak protective association between homozygotes A/A, heterozygotes 
A/G (V57I) and A/T (F31I) genotype and reduced risk for perineural invasion. In another 
study we performed the case-control study of selected polymorphisms rs151658 and 
rs239559, rs1031963 and rs1801376 in mitotic segregation genes, TTK and BUB1B, 
respectively (Hudler et al., 2010). We found a significant interaction between patients and 
control cases for genotype A/G in rs151658 polymorphism. We also observed a statistically 
important difference in genotype frequencies between female patients and control cases for 
polymorphism rs1801376. Our results showed that this difference was significant only for 
female population of patients. Polymorphisms rs151658, rs1031963 and rs1801376 showed 
significant associations with certain clinicopathological factors, such as differentiation of 
tumours, infiltration, and intestinal type of gastric cancers. This study provides new support 
for the role of mitotic genes in gastric cancer development, suggesting that smaller changes 
could be associated with genetically unstable gastric tumours. However, the biological basis 
for the role of risk alleles of mitotic genes in cancers of the upper gastrointestinal tract needs 
to be established to understand its consequences and role during carcinogenesis. 
Carcinogens are a second probable cause of CIN and particular agents, such as Helicobacter 
pylori infection, tobacco, nitrates, and nitrites have an important impact on gastric 
tumorigenesis in genetically susceptible individuals (Matysiak-Budnik & Megraud, 2006). In 
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addition, a combination of SNPs within pro-inflammatory genes IL-1┚, IL-1RA, TNF┙, and 
IL-10 conferred even greater risk for gastric cancer development in combination with CIN 
causing Helicobacter pylori infection (El-Omar et al., 2003).  
3. Future directions 
Recent advances in high-throughput methods revealed the lack of consistency regarding the 
number and species of genes mutated in all subtypes of gastric adenocarcinomas, or even 
from one cell to another within the same tumour, which points to amazing genetic diversity 
of cancer cells. The idea that mutations in a few specific genes are necessary and sufficient to 
cause the disease in any of the most common human cancer forms was opposed by 
observation that random mutations accumulate much faster inside genetically unstable 
malignant cells and that genome instability might be a critical early event that leads to the 
mutation of oncogenes and suppressor genes. Furthermore, in contrast to gene mutation 
hypotheses neoplastic transformation of normal epithelial cells is a slow process, which 
explains the fact that majority of cancers appear at an advanced age. All these facts make 
relevant molecular cancer diagnosis and treatment extremely complex and difficult to fulfil. 
Therefore, in the future we suggest performing combined analyses of gene expression 
profiles, genetic polymorphisms in mitotic genes, and functional analyses of these 
polymorphisms. Studies should be expanded on candidate genes by employing genome-
wide association studies in order to identify novel genetic variants associated with gastric 
cancer.   
4. Conclusion 
It is apparent that majority of gastric cancers are characterized by genetic instability, either 
MSI or CIN. Whereas MSI is characterized by changes in short repeat sequences, the 
hallmark of CIN are gross chromosomal rearrangements, such as the gain or loss of whole 
chromosomes (Martin et al., 2010). Accumulating evidence shows that CIN and aneuploidy 
are the most common characteristics of sporadic gastric adenocarcinomas, accounting for 
more than 60% of cases, whereas MSI is characteristic for hereditary type of gastric cancer, 
developed in the context of Lynch syndrome, and a smaller subset of sporadic cancers, 
ranging from 15% to 35% (Panani, 2008). The newly formed chromosomal/aneuploidy 
hypothesis (aneuploidy could be the consequence of carcinogens or genetic changes in 
certain mitotic genes) could answer several questions remaining from the currently 
established classic oncogene overexpression model, mutator and suppressor theories, which 
postulate that cancer is caused by clonal expansion of one single cell, which has 
accumulated 4-7 mutations during the lifetime of a patient. (Castro et al., 2007; Duesberg et 
al., 2005; Duesberg et al., 2000). However, these theories do not explain the long latent 
periods in cancer development and more importantly, despite more than two decades of 
effort, they have failed to identify a particular sets of gene mutations that occur in every 
instance of gastric tumour development.  
It is evident that gastric cancer is the consequence of a multistep process involving different 
genetic and epigenetic changes in numerous genes. Host genetic background and 
environmental factors also play an important role in the pathogenesis of the disease. The 
majority of genetic alterations contributing to the malignant transformation were observed 
in growth regulatory genes, and in genes involved in cell cycle progression and arrest. 
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However, exact genetic steps involved in the stomach carcinogenesis still remain uncertain. 
Different histological forms, as well as different aetiologies point to different genetic 
pathways for intestinal and diffuse tumours. To date, no single genomic abnormality is 
known to be specific to sporadic gastric cancer, or to any of its histological subtypes. Some 
of the genetic changes occur commonly in both major types, intestinal and diffuse, but some 
differ depending on the histological type. Even more, recent studies supported the idea that 
there are subgroups where MSI, CIN, suppressor, and methylator pathways overlap during 
the development of malignant phenotype. In conclusion, further research is required, with 
emphasis on collecting as many genetic changes as possible, which could aid in deciphering 
the molecular mechanisms of gastric cancer and in the development of suitable methods for 
screening, risk assessment and prognostic evaluation.  
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